Stay updated on Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page.

Latest updates to the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4. This indicates a minor metadata version upgrade for the page.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedUpdated the website revision indicator in the page footer from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

- Check31 days agoChange DetectedThe page revision tag was updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded the iRECIST guidelines citation (Lancet Oncology, 2017) to the Publications section and removed the associated erratum notice (Lancet Oncology, 2019).SummaryDifference0.1%

- Check60 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check75 days agoChange DetectedUpdated iRECIST guideline reference to the 3.4.3 revision (including the erratum) and removed the older 3.4.2 citation.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Epacadostat Combo in Bladder Cancer Clinical Trial page.